Head to Head Survey: Bausch + Lomb (NYSE:BLCO) vs. NewGenIvf Group (NASDAQ:NIVF)

NewGenIvf Group (NASDAQ:NIVF) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.

Profitability

This table compares NewGenIvf Group and Bausch + Lomb’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NewGenIvf Group	N/A	N/A	N/A
Bausch + Lomb	-6.13%	2.42%	1.15%

Institutional and Insider Ownership

66.2% of NewGenIvf Group shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 31.8% of NewGenIvf Group shares are owned by insiders. Comparatively, 0.8% of Bausch + Lomb shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

NewGenIvf Group has a beta of -0.08, suggesting that its share price is 108% less volatile than the S&P 500. Comparatively, Bausch + Lomb has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for NewGenIvf Group and Bausch + Lomb, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewGenIvf Group	1	0	0	0	1.00
Bausch + Lomb	2	8	5	0	2.20

Bausch + Lomb has a consensus target price of $17.00, suggesting a potential upside of 0.95%. Given Bausch + Lomb’s stronger consensus rating and higher possible upside, analysts plainly believe Bausch + Lomb is more favorable than NewGenIvf Group.

Valuation and Earnings

This table compares NewGenIvf Group and Bausch + Lomb”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewGenIvf Group	$5.43 million	0.10	-$520,000.00	N/A	N/A
Bausch + Lomb	$4.79 billion	1.24	-$317.00 million	($0.87)	-19.36

NewGenIvf Group has higher earnings, but lower revenue than Bausch + Lomb.

Summary

Bausch + Lomb beats NewGenIvf Group on 8 of the 12 factors compared between the two stocks.

About NewGenIvf Group

NewGenIVF Group Ltd. operates as an assisted reproductive services provider. It focuses on providing fertility treatments to fulfil the dreams of building families. The firm offers in-vitro fertilization treatment service, comprising traditional IVF and egg donation, and surrogacy and ancillary caring services. The company was founded by Siu Wing Fung and Fong Hei Yue on January 16, 2019 and is headquartered in Bangkok, Thailand.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.